S1809
Physics - Dose prediction/calculation, optimisation and applications for photon and electron planning
ESTRO 2026
optimization objectives were incorporated. Direct application of the model failed to meet local target dose coverage requirements, highlighting the importance of site-specific review and adjustment when transferring KBP models between institutions. Nevertheless, the use of the model reduced inter- planner variability and planning time, supporting the feasibility of implementing externally developed KBP models in clinical routine after appropriate local validation. Keywords: knowledge-based planning, prostate, Rapidplan Optimizing Treatment Planning for Acoustic Neuromas with CyberKnife SRS: Preliminary Outcome Analysis Federica Murtas 1 , Antonella Bufacchi 1 , Federica Pavoncello 2 , Maria Vittoria Leone 2 , Giulia Rambaldi Guidasci 1 , Giuseppe Maria Della Pepa 3 , Giuseppe Minniti 2 , Francesco Miccichè 2 , Tiziana Malatesta 1 1 Centro di Eccellenza Oncologia Radioterapica, Medica e Diagnostica per Immagini - UOS Fisica Sanitaria, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy. 2 Centro di Eccellenza Oncologia Radioterapica, Medica e Diagnostica per Immagini – UOC Radioterapia, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy. Digital Poster 794 Purpose/Objective: Acoustic neuroma (AN) is a benign tumor of the vestibulocochlear nerve, accounting for 6–10% of intracranial neoplasms. Stereotactic radiosurgery (SRS), either single- or multi-fraction, represents a valid alternative to microsurgery, offering excellent tumor control and low morbidity. This study reports treatment planning details and early clinical outcomes in AN patients treated with the CyberKnife® (CK) system. Material/Methods: Fifty consecutive patients with volume-enhanced AN were treated with CK over an 18-months period. Retrospective analysis included demographics, symptoms, Koos stage, and SRS type—single-fraction (12 Gy) or 3-fraction (3 × 6 Gy). Follow-up was conducted at 1, 3 months and then every 6 months. Median follow-up was 10 months (range: 5–15).Median 3 UOC Neurochirurgia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy GTV was 0.48 cc [0.16–1.20] in the single-fraction group and 1.93 cc [0.48–5.82] in the fractionated group. Prescription dose corresponded to 80.9% [77.7–85.2] of the maximum dose, with mean treatment duration of 34.8 ± 5.5 minutes. Plans used circular collimators, with a median of 82 [39–121] nodes and 129 [54–233] beams. Dose conformity was
Conclusion: The externally developed RapidPlan model generated prostate-only radiotherapy plans of comparable or superior quality to the clinical plans, once CTV
Made with FlippingBook - Share PDF online